Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
60 Degrees Pharmaceuticals, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
SXTP
Nasdaq
2830
www.60degreespharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for 60 Degrees Pharmaceuticals, Inc.
Harrow (HROW) Q3 Earnings Lag Estimates
- Nov 9th, 2026 3:35 pm
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates
- Nov 5th, 2026 6:35 am
Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization
- Nov 4th, 2026 2:15 pm
60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
- Oct 28th, 2026 6:30 am
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
- Oct 27th, 2026 6:06 am
60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting
- Oct 6th, 2026 8:44 am
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
- Oct 6th, 2026 6:10 am
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
- Oct 2nd, 2026 7:00 am
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
- Oct 1st, 2026 6:03 am
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
- Aug 14th, 2026 1:47 pm
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
- Aug 10th, 2026 6:05 pm
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
- Aug 6th, 2026 5:10 am
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
- Jul 30th, 2026 12:23 pm
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
- Jul 29th, 2026 2:03 pm
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
- Jul 8th, 2026 6:01 am
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
- Jul 1st, 2026 6:02 am
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
- Jun 11th, 2026 6:03 am
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
- May 26th, 2026 6:02 am
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
- May 15th, 2026 6:42 am
Scroll